MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
December 05, 2024 18:00 ET | Source: MediciNova, Inc. LA JOLLA, Calif.,…
Interim Report January September 2024
Third quarter 2024 (compared to third quarter 2023) Net sales for the…
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
November 15, 2024 17:52 ET | Source: Protara Therapeutics NEW YORK, Nov.…
Aino Health AB (publ): interim report january-september 2024
This document in English is a translation of the original in Swedish.…
Bavarian Nordic Announces Interim Results for the First Nine Months of 2024
COPENHAGEN, Denmark, November 15, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced…